SEC Comment Letter for Immunovant, Inc. (IMVT) (CIK 0001764013) (IMVT) — Feb 2, 2021
Immunovant, Inc. (IMVT) (CIK 0001764013)
Date: Feb. 2, 2021 · CIK: 0001764013 · Accession: 0000000000-21-001281
AI Filing Summary & Sentiment
File numbers found in text: 001-38906
Letter
United States securities and exchange commission logo February 2, 2021 Pamela Yanchik Connealy Chief Financial Officer Immunovant, Inc. 320 West 37th Street New York, NY 10018 Re:Immunovant, Inc. Form 10-K for Fiscal Year Ended March 31, 2020 Filed June 29, 2020 File No. 001-38906 Dear Ms. Connealy: We have limited our review of your filing to the financial statements and related disclosures and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to the comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to the comment, we may have additional comments. Form 10-K for Fiscal Year Ended March 31, 2020 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations Financial Operations Overview Research and Development Expenses, page 93 1.Please disclose, in proposed disclosure to be provided in future filings, the costs incurred during each period presented for each of your key research and development projects. If you do not track your research and development costs by project, please disclose that fact and explain why you do not maintain and evaluate research and development costs by project. Provide other quantitative or qualitative disclosure that provides more transparency as to the type of research and development expenses incurred (i.e. by nature or type of expense) which should reconcile to total research and development expense on the Combined and Consolidated Statements of Operations.
FirstName LastNamePamela Yanchik Connealy Comapany NameImmunovant, Inc. February 2, 2021 Page 2 FirstName LastName Pamela Yanchik Connealy Immunovant, Inc. February 2, 2021 Page 2 In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. You may contact Sasha Parikh at 202-551-3267 or Tracie Mariner at 202-551-3744 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
February 2, 2021
Pamela Yanchik Connealy
Chief Financial Officer
Immunovant, Inc.
320 West 37th Street
New York, NY 10018
Re:Immunovant, Inc.
Form 10-K for Fiscal Year Ended March 31, 2020
Filed June 29, 2020
File No. 001-38906
Dear Ms. Connealy:
We have limited our review of your filing to the financial statements and related
disclosures and have the following comment. In our comment, we may ask you to provide us
with information so we may better understand your disclosure.
Please respond to the comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to the comment, we may have additional comments.
Form 10-K for Fiscal Year Ended March 31, 2020
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
Financial Operations Overview
Research and Development Expenses, page 93
1.Please disclose, in proposed disclosure to be provided in future filings, the costs incurred
during each period presented for each of your key research and development projects. If
you do not track your research and development costs by project, please disclose that fact
and explain why you do not maintain and evaluate research and development costs by
project. Provide other quantitative or qualitative disclosure that provides more
transparency as to the type of research and development expenses incurred (i.e. by nature
or type of expense) which should reconcile to total research and development expense on
the Combined and Consolidated Statements of Operations.
FirstName LastNamePamela Yanchik Connealy
Comapany NameImmunovant, Inc.
February 2, 2021 Page 2
FirstName LastName
Pamela Yanchik Connealy
Immunovant, Inc.
February 2, 2021
Page 2
In closing, we remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
You may contact Sasha Parikh at 202-551-3267 or Tracie Mariner at 202-551-3744 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences